Message from the President

PRINT

Even as the struggle against previously-unknown-in-humans infectious disease is becoming entrenched as the new normal, geopolitical risks are intensifying, creating new social concerns and expanding uncertainties. On the other hand, scientific advances including new technological breakthroughs are providing opportunities to address various challenges.

In 2023 we enter the final year of our Third Medium-Term Management Plan, defined as Advance in the Global Market as a Unique, Total Healthcare Company: Five-Year Growth Phase. In 2022, our Pharmaceutical business was driven by continued robust growth of the product categories we have positioned as our four global prescription drug products. Additionally, we were buoyed by several major achievements: approval of two original anti-cancer agents and the application of the approval of our new ultrasound renal denervation system – which addresses unmet needs for the treatment of uncontrolled hypertension. In our Nutraceutical business, functional beverage sales grew, both in Japan and in global markets, and we made headway in our efforts to nurture the women’s health market. We also launched a new brand in our line of Cosmedics* that focuses on healthy skin. At the same time, we are steadily taking steps towards our 2050 Environmental Vision, Net Zero, with the aim of reducing the total environmental impact across all our business activities to zero.

Amidst massive transformation of the social environment, we remain steadfast in our commitment as a total healthcare company to providing solutions to increasingly deepening and diversifying health-related needs. Under our corporate philosophy, Otsuka-people creating new products for better health worldwide, we will continue to contribute to the health and well-being of people around the world.

We look forward to your ongoing support.


President and Representative Director, CEO

*Cosmedics = cosmetics + medicine

TOP